2 melanoma drugs from GSK win Canadian OK

07/26/2013 | Pharmaceutical Business Review Online

Health Canada approved GlaxoSmithKline's BRAF-inhibitor Tafinlar, or dabrafenib mesylate, and first-in-class MEK-inhibitor Mekinist, or trametinib, to treat melanoma patients with BRAF V600 mutation. The drugs are indicated as oral monotherapy for metastatic melanoma or unresectable melanoma. Tafinlar will be available in 75 mg and 50 mg capsules, and Mekinist in 2.0 mg and 0.5 mg tablets.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX